Related Experiment Video
Updated: Apr 19, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Neuroendocrine Merkel cell carcinoma is associated with mutations in key DNA repair, epigenetic and apoptosis
Christian A Graves1, Ashley Jones, Justin Reynolds
1University of South Carolina School of Medicine, Columbia, S.C., USA.
Introduction:
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma with a poorly understood molecular etiology. We implemented a comprehensive deep sequencing approach to identify mutations in the tumor DNA from a cohort of patients treated at our institution over the past 15 years. Our results indicate mutations that may constitute therapeutic targets in MCC.
Methods:
Five patients were treated for MCC within the study interval. Patients with adequate tissue (n = 4), positive neuroendocrine differentiation (chromogranin, synaptophysin, and cytokeratin 20), and histopathological confirmation of MCC were included in the study. DNA was extracted from archival tumor tissue samples and analyzed by massively parallel sequencing using a targeted, multiplex PCR approach followed by semiconductor sequencing.
Results:
We demonstrate high-penetrance nonsense mutations in PDE4DIP (n = 4) as well as various missense mutations in the DNA damage response (PRKDC, AURKB, ERCC5, ATR, and ATRX) and epigenetic modulating enzymes (MLL3).
Conclusion:
We describe several mutations in potential disease-relevant genes and pathways. These targets should be evaluated in a larger cohort to determine their role in the molecular pathogenesis of MCC.
Insights
Deep sequencing identified mutations in Merkel cell carcinoma (MCC), a rare cancer. Key findings include PDE4DIP mutations and alterations in DNA damage response and epigenetic pathways, suggesting potential therapeutic targets for MCC.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with an unclear molecular basis.
- Understanding MCC's genetic underpinnings is crucial for developing effective treatments.
Purpose of the Study:
- To identify novel mutations and molecular targets in Merkel cell carcinoma.
- To investigate the genetic landscape of MCC using comprehensive deep sequencing.
Main Methods:
- Analysis of tumor DNA from five MCC patients using targeted, multiplex PCR and semiconductor sequencing.
- Histopathological confirmation and assessment of neuroendocrine differentiation were performed.
Main Results:
- High-penetrance nonsense mutations were found in PDE4DIP in four patients.
- Missense mutations were identified in DNA damage response genes (PRKDC, AURKB, ERCC5, ATR, ATRX) and epigenetic modifiers (MLL3).
Conclusions:
- Several mutations in disease-relevant genes and pathways were identified in MCC.
- These genetic alterations represent potential therapeutic targets for MCC.
- Further evaluation in larger patient cohorts is needed to confirm their role in MCC pathogenesis.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:23Abnormal Proliferation
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...